Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Convertible Debt (2023 - 2025)

Mirum Pharmaceuticals (MIRM) has 3 years of Convertible Debt data on record, last reported at $309.8 million in Q4 2025.

  • For Q4 2025, Convertible Debt rose 0.56% year-over-year to $309.8 million; the TTM value through Dec 2025 reached $309.8 million, up 0.56%, while the annual FY2025 figure was $309.8 million, 0.56% up from the prior year.
  • Convertible Debt reached $309.8 million in Q4 2025 per MIRM's latest filing, roughly flat from $309.4 million in the prior quarter.
  • Across five years, Convertible Debt topped out at $309.8 million in Q4 2025 and bottomed at $305.6 million in Q2 2023.
  • Average Convertible Debt over 3 years is $307.7 million, with a median of $307.7 million recorded in 2024.
  • Peak YoY movement for Convertible Debt: grew 0.53% in 2024, then grew 0.56% in 2025.
  • A 3-year view of Convertible Debt shows it stood at $306.4 million in 2023, then grew by 0.54% to $308.1 million in 2024, then rose by 0.56% to $309.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Convertible Debt were $309.8 million in Q4 2025, $309.4 million in Q3 2025, and $308.9 million in Q2 2025.